NCT03328078 2026-04-16
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Phase 1/2 Recruiting
Clinical Trials
84 trialsNCT04521231 2026-04-16
A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Amgen
Phase 1/2 Recruiting
NCT07500753 2026-04-15
A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients
The First Affiliated Hospital of Soochow University
Phase NA Recruiting
NCT05996185 2026-04-14
Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Yale University
Phase 2 Recruiting
NCT05283720 2026-04-13
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Genmab
Phase 2 Recruiting
NCT07257419 2026-04-13
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
St. Jude Children's Research Hospital
Phase 1 Recruiting
NCT07523555 2026-04-13
ADAPT-HEM
Beijing Biotech
Phase 1/2 Recruiting
NCT05010005 2026-04-09
A Study of Ruxolitinib and Duvelisib in People With Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06713837 2026-04-08
IMPACT-AML
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 3 Recruiting
NCT07511426 2026-04-06
U96-CAR-T-Cells For R/R B-ALL
The First Affiliated Hospital of Soochow University
Phase 1 Recruiting
NCT05544968 2026-04-03
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Recruiting
NCT04094311 2026-04-02
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT06660368 2026-04-01
BCL2i CLAG-M in R/R Acute Myeloid Leukemia
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04716452 2026-03-31
KNAN2001
Keystone Nano, Inc
Phase 1 Recruiting
NCT06542250 2026-03-27
TITANium
AstraZeneca
Phase 1/2 Recruiting
NCT04988555 2026-03-24
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT03838926 2026-03-16
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Vanda Pharmaceuticals
Phase 1 Recruiting
NCT04588922 2026-03-16
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Sellas Life Sciences Group
Phase 1/2 Recruiting
NCT05292664 2026-03-12
Venetoclax Basket Trial for High Risk Hematologic Malignancies
Dana-Farber Cancer Institute
Phase 1 Recruiting
NCT05748197 2026-03-10
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT06459024 2026-03-10
IMPACT STREAM
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Recruiting
NCT06173518 2026-03-02
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited
Phase 1 Recruiting
NCT03826992 2026-02-18
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
Children's Hospital Medical Center, Cincinnati
Phase 1 Recruiting
NCT06644183 2026-02-11
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
NCT07070219 2026-02-05
TENACITY-01
BIOHENG THERAPEUTICS US LLC
Phase 1/2 Recruiting
NCT07366801 2026-01-26
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 2/3 Recruiting
NCT01853631 2026-01-05
SAGAN
Baylor College of Medicine
Phase 1 Recruiting
NCT07173595 2026-01-02
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
Qilu Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT05657652 2025-12-29
CAV Regimen for R/R Ph- B-ALL
The First Affiliated Hospital of Soochow University
Phase NA Recruiting
NCT07167381 2025-12-23
xDRIVE for Florida-based Cancer Patients
First Ascent Biomedical Inc.
Phase NA Recruiting
NCT06232655 2025-12-19
Cladribine Venetoclax in Monocytic AML
University of Colorado, Denver
Phase 2 Recruiting
NCT06761586 2025-12-18
VIJAY-1
Aurigene Discovery Technologies Limited
Phase 1 Recruiting
NCT06649227 2025-12-05
CARLA-M19
University Hospital, Lille
Phase 1 Recruiting
NCT06064903 2025-12-02
CD7-CAR01
Bambino Gesù Hospital and Research Institute
Phase 1/2 Recruiting
NCT06812104 2025-11-18
Clinical Trial of KK2845 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Kyowa Kirin Co., Ltd.
Phase 1 Recruiting
NCT05010564 2025-11-13
TRICAR-ALL
Baylor College of Medicine
Phase 1 Recruiting
NCT05780034 2025-10-02
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Accutar Biotechnology Inc
Phase 1 Recruiting
NCT06730256 2025-10-01
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
The First Affiliated Hospital of Soochow University
Phase EARLY_PHASE1 Recruiting
NCT05924750 2025-09-26
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Recruiting
NCT06704152 2025-09-18
BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS
BlueSphere Bio, Inc
Phase 1/2 Recruiting
NCT05658640 2025-09-16
HEM-iSMART D
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05745714 2025-09-16
HEM-iSMART C
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05751044 2025-09-16
HEM-iSMART B
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT03850574 2025-08-26
TUSCANY
Aptose Biosciences Inc.
Phase 1/2 Recruiting
NCT06786533 2025-08-14
Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML
Hemogenyx Pharmaceuticals LLC
Phase 1 Recruiting
NCT04684147 2025-08-08
Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia
Juventas Cell Therapy Ltd.
Phase 2 Recruiting
NCT06340737 2025-08-07
AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
Stanford University
Phase 1 Recruiting
NCT07105579 2025-08-06
Effectiveness and Safety of Blinatumomab and Donor Lymphocyte Infusion in Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for High-risk Ph Negative B Cell Acute Lymphoblastic Leukemia
First Affiliated Hospital of Zhejiang University
Phase 2 Recruiting
NCT06810778 2025-07-15
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Jonsson Comprehensive Cancer Center
Phase 1/2 Recruiting
NCT05963217 2025-07-02
Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL
University Health Network, Toronto
Phase 1 Recruiting